Quinapril

Drug Profile

Quinapril

Alternative Names: Accupril; Accuretic; Accuzide

Latest Information Update: 14 Jan 2011

Price : $50

At a glance

  • Originator Pfizer
  • Developer Mitsubishi Pharma Corporation; Nonindustrial source; Pfizer
  • Class Antihypertensives; Heart failure therapies; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Heart failure; Hypertension
  • No development reported Myocardial ischaemia

Most Recent Events

  • 07 Jun 2013 Biomarkers information updated
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 20 Oct 2003 A study has been added to the adverse events and Heart Failure therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top